Skip to main content

Table 2 Univariate COX regression analysis for the risk factors for progression (PFS) and time-to-failure (TTF) in Fulvestrant users

From: Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients

Covariates

Level

PFS

TTF

Hazard ratio (95% CI)

p-value

Hazard ratio (95% CI)

p-value

Fulvestrant usage

First line

Ref

 

Ref

 
 

Second line

1.911 (0.803, 4.547

0.14

2.008 (0.849, 4.745)

0.11

 

≥ Third line

2.420 (1.026, 5.711)

0.04

2.668 (1.135, 6.272)

0.03

Age at diagnosis (years)

 

1.001 (0.977, 1.026)

0.94

1.004 (0.981, 1.028)

0.72

Age at FX usage (years)

 

0.990 (0.966, 1.015)

0.44

0.994 (0.971, 1.017)

0.60

 

< 62

Ref

 

Ref

 
 

≥ 62

0.753 (0.441, 1.288)

0.30

0.714 (0.425, 1.199)

0.20

Weight

 

0.999 (0.982, 1.016)

0.37

0.997 (0.979, 1.015)

0.75

DFS (years)

 

0.950 (0.886, 1.019)

0.15

0.948 (0.887, 1.013)

0.11

ER

Negative

0.610 (0.128, 2.903)

0.53

0.795 (0.168, 3.763)

0.77

 

1%–50%

Ref

 

Ref

 
 

50%–100%

0.693 (0.318, 1.510)

0.36

0.869 (0.404, 1.869)

0.72

 

Unknown

0.706 (0.326, 1.528)

0.71

0.894 (0.417, 1.916)

0.77

PR

Negative

Ref

 

Ref

 
 

Positive

1.171 (0.602, 2.277)

0.64

1.073 (0.582, 1.981)

0.82

HER2

Negative

Ref

 

Ref

 
 

Positive

2.024 (0.997, 4.109)

0.05

1.833 (0.936, 3.587)

0.08

Nuclear or histological grade

2

Ref

 

Ref

 

3

1.683 (0.942, 3.004)

0.08

1.476 (0.861, 2.530)

0.15

 

Unknown

1.410 (0.782, 2.541)

0.25

1.219 (0.694, 2.139)

0.49

Stage at BC diagnosis

0/I

Ref

 

Ref

 
 

II

1.476 (0.791, 2.755)

0.22

1.378 (0.759, 2.503)

0.29

 

III/IV

1.709 (1.001, 2.919)

0.05

1.607 (0.969, 2.666)

0.07

Menopause

Natural menupause

Ref

 

Ref

 
 

OFS (OFS + surgery)

0.850 (0.463, 1.560)

0.60

0.697 (0.384, 1.265)

0.24

 

Surgery

1.145 (0.673, 1.948)

0.62

1.049 (0.624, 1.764)

0.86

Treatment of primary diagnosis

Primary site surgery

0.807 (0.112, 5.837)

0.83

0.515 (0.126, 2.107)

0.36

Primary site Radiation

1.075 (0.688, 1.682)

0.75

1.133 (0.738, 1.740)

0.57

 

Chemotherapy

0.995 (0.495, 2.003)

1.00

0.968 (0.499, 1.881)

0.92

 

Endocrine therapy

1.223 (0.729, 2.049)

0.45

1.263 (0.771, 2.068)

0.35

Treatment after relapse or metastasis

Radiation (Yes vs No)

1.091 (0.589, 2.022)

0.78

0.879 (0.476, 1.621)

0.68

Chemotherapy (Yes vs No)

1.394 (0.873, 2.226)

0.16

1.413 (0.905, 2.206)

0.13

Metastatic sites

Lymph nodes

1.623 (1.041, 2.531)

0.03

1.509 (0.986, 2.311)

0.06

 

Bone

1.096 (0.682, 1.762)

0.83

1.180 (0.745, 1.869)

0.57

 

Visceral

1.036 (0.671, 1.601)

0.87

0.967 (0.637, 1.468)

0.87